These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 28145465)

  • 21. [Prognostic value of important driver gene mutations in patients with radical resection of pancreatic cancer].
    Shen J; Gao SZ; Wang H; Shi XH; Li B; Pan YQ; Shen S; Shao Z; Guo SW; Jin G
    Zhonghua Wai Ke Za Zhi; 2019 Nov; 57(11):840-847. PubMed ID: 31694133
    [No Abstract]   [Full Text] [Related]  

  • 22. Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic Cancer.
    Hayashi H; Kohno T; Ueno H; Hiraoka N; Kondo S; Saito M; Shimada Y; Ichikawa H; Kato M; Shibata T; Morizane C; Sakamoto Y; Shimada K; Komatsu Y; Sakamoto N; Okusaka T
    Pancreas; 2017 Mar; 46(3):335-340. PubMed ID: 28099251
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Distinction of Invasive Carcinoma Derived From Intraductal Papillary Mucinous Neoplasms From Concomitant Ductal Adenocarcinoma of the Pancreas Using Molecular Biomarkers.
    Tamura K; Ohtsuka T; Date K; Fujimoto T; Matsunaga T; Kimura H; Watanabe Y; Miyazaki T; Ohuchida K; Takahata S; Ishigami K; Oda Y; Mizumoto K; Nakamura M; Tanaka M
    Pancreas; 2016 Jul; 45(6):826-35. PubMed ID: 26646266
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical significance of the genetic landscape of pancreatic cancer and implications for identification of potential long-term survivors.
    Yachida S; White CM; Naito Y; Zhong Y; Brosnan JA; Macgregor-Das AM; Morgan RA; Saunders T; Laheru DA; Herman JM; Hruban RH; Klein AP; Jones S; Velculescu V; Wolfgang CL; Iacobuzio-Donahue CA
    Clin Cancer Res; 2012 Nov; 18(22):6339-47. PubMed ID: 22991414
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phosphatase PPM1A is a novel prognostic marker in pancreatic ductal adenocarcinoma.
    Fan J; Yang MX; Ouyang Q; Fu D; Xu Z; Liu X; Mino-Kenudson M; Geng J; Tang F
    Hum Pathol; 2016 Sep; 55():151-8. PubMed ID: 27195906
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pancreatic ductal adenocarcinomas from Mexican patients present a distinct genomic mutational pattern.
    Sanchez P; Espinosa M; Maldonado V; Barquera R; Belem-Gabiño N; Torres J; Cravioto A; Melendez-Zajgla J
    Mol Biol Rep; 2020 Jul; 47(7):5175-5184. PubMed ID: 32583281
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Longitudinal analysis of cell-free mutated KRAS and CA 19-9 predicts survival following curative resection of pancreatic cancer.
    Hussung S; Akhoundova D; Hipp J; Follo M; Klar RFU; Philipp U; Scherer F; von Bubnoff N; Duyster J; Boerries M; Wittel U; Fritsch RM
    BMC Cancer; 2021 Jan; 21(1):49. PubMed ID: 33430810
    [TBL] [Abstract][Full Text] [Related]  

  • 28. KRAS mutations in codon 12 or 13 are associated with worse prognosis in pancreatic ductal adenocarcinoma.
    Sinn BV; Striefler JK; Rudl MA; Lehmann A; Bahra M; Denkert C; Sinn M; Stieler J; Klauschen F; Budczies J; Weichert W; Stenzinger A; Kamphues C; Dietel M; Riess H
    Pancreas; 2014 May; 43(4):578-83. PubMed ID: 24681874
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intra-pancreatic Distal Bile Duct Carcinoma is Morphologically, Genetically, and Clinically Distinct from Pancreatic Ductal Adenocarcinoma.
    Deshpande V; Konstantinidis IT; Castillo CF; Hezel AF; Haigis KM; Ting DT; Bardeesy N; Goyal L; Zhu AX; Warshaw AL; Lillemoe KD; Ferrone CR
    J Gastrointest Surg; 2016 May; 20(5):953-9. PubMed ID: 26956004
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pancreatic Cancer: "A Riddle Wrapped in a Mystery inside an Enigma".
    Borazanci E; Dang CV; Robey RW; Bates SE; Chabot JA; Von Hoff DD
    Clin Cancer Res; 2017 Apr; 23(7):1629-1637. PubMed ID: 28373361
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular characteristics of early-onset pancreatic ductal adenocarcinoma.
    Debernardi S; Liszka L; Ntala C; Steiger K; Esposito I; Carlotti E; Baker AM; McDonald S; Graham T; Dmitrovic B; Feakins RM; Crnogorac-Jurcevic T
    Mol Oncol; 2024 Mar; 18(3):677-690. PubMed ID: 38145461
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers.
    Singhi AD; George B; Greenbowe JR; Chung J; Suh J; Maitra A; Klempner SJ; Hendifar A; Milind JM; Golan T; Brand RE; Zureikat AH; Roy S; Schrock AB; Miller VA; Ross JS; Ali SM; Bahary N
    Gastroenterology; 2019 Jun; 156(8):2242-2253.e4. PubMed ID: 30836094
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel hotspot and rare somatic mutation p.A138V, at TP53 is associated with poor survival of pancreatic ductal and periampullary adenocarcinoma patients.
    Saha G; Singh R; Mandal A; Das S; Chattopadhyay E; Panja P; Roy P; DeSarkar N; Gulati S; Ghatak S; Ghosh S; Banerjee S; Roy B; Ghosh S; Chaudhuri D; Arora N; Biswas NK; Sikdar N
    Mol Med; 2020 Jun; 26(1):59. PubMed ID: 32552660
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alterations in Tumor DNA Are Related to Short Postoperative Survival in Patients Resected for Pancreatic Carcinoma Aimed at Cure.
    Asting AG; Ljungman D; Carén H; Dambrauskas Z; Iresjö BM; Hyltander A; Naredi P; Lundholm K
    Pancreas; 2016 Jul; 45(6):900-7. PubMed ID: 26684859
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetics and Biology of Pancreatic Ductal Adenocarcinoma.
    Dunne RF; Hezel AF
    Hematol Oncol Clin North Am; 2015 Aug; 29(4):595-608. PubMed ID: 26226899
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low frequency of KRAS mutation in pancreatic ductal adenocarcinomas in Korean patients and its prognostic value.
    Kwon MJ; Jeon JY; Park HR; Nam ES; Cho SJ; Shin HS; Kwon JH; Kim JS; Han B; Kim DH; Choi YL
    Pancreas; 2015 Apr; 44(3):484-92. PubMed ID: 25513781
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical study of genomic drivers in pancreatic ductal adenocarcinoma.
    Barrett MT; Deiotte R; Lenkiewicz E; Malasi S; Holley T; Evers L; Posner RG; Jones T; Han H; Sausen M; Velculescu VE; Drebin J; O'Dwyer P; Jameson G; Ramanathan RK; Von Hoff DD
    Br J Cancer; 2017 Aug; 117(4):572-582. PubMed ID: 28720843
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A human cancer xenograft model utilizing normal pancreatic duct epithelial cells conditionally transformed with defined oncogenes.
    Inagawa Y; Yamada K; Yugawa T; Ohno S; Hiraoka N; Esaki M; Shibata T; Aoki K; Saya H; Kiyono T
    Carcinogenesis; 2014 Aug; 35(8):1840-6. PubMed ID: 24858378
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pancreatic adenocarcinomas without KRAS, TP53, CDKN2A and SMAD4 mutations and CDKN2A/CDKN2B copy number alterations: a review of the genomic landscape to unveil therapeutic avenues.
    Voutsadakis IA; Digklia A
    Chin Clin Oncol; 2023 Feb; 12(1):2. PubMed ID: 36922358
    [TBL] [Abstract][Full Text] [Related]  

  • 40. DPC4/Smad4 expression and outcome in pancreatic ductal adenocarcinoma.
    Biankin AV; Morey AL; Lee CS; Kench JG; Biankin SA; Hook HC; Head DR; Hugh TB; Sutherland RL; Henshall SM
    J Clin Oncol; 2002 Dec; 20(23):4531-42. PubMed ID: 12454109
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.